The management department of GEM companies of Shenzhen Stock Exchange issued an inquiry letter on non licensed restructuring to Guangdong Vtr Bio-Tech Co.Ltd(300381) on February 16. On January 29, the company disclosed that it planned to sell all the equity of xinhexin, keyixin and Lihua pharmaceutical in cash.
Shenzhen stock exchange requires the company to explain the transaction plan in detail, clearly list the sequence and time required for the transaction steps such as Xinhe new capital increase, Xinhe new, Keyi new debt settlement, Xinhe new, Keyi new equity transfer, as well as the sequence of Lihua pharmaceutical debt settlement and Lihua pharmaceutical equity transfer, and explain whether the transaction constitutes a connected transaction; Quantitative description of the funds needed to build a “global core enterprise of steroid hormone API” and develop “biological enzyme preparation, animal nutrition and health”, and the necessity of stripping the pharmaceutical sector in combination with the situation that the target company accounts for a relatively high proportion of operating revenue, accumulated continuous profits in the historical period and the company’s asset liability ratio is not significantly higher than that of comparable companies, And explain whether the company’s continuous profitability will be adversely affected after stripping relevant assets; Explain whether the biological enzyme preparation and functional feed business can support the company to maintain or improve its sustainable operation ability; Disclose the ultimate actual controller of desaino, the controlling shareholder of Lihua pharmaceutical’s counterparty, and explain whether it has an associated relationship with Liu Xirong, the actual controller of Xinhe Xinhe or other counterparties; Whether Yuanli investment and Shengchuang pharmaceutical are specially set up for this transaction, and explain whether there is a risk of failure to pay relevant funds on time.
